Cargando…

Prognostic value of metastin expression in human pancreatic cancer

BACKGROUND: KiSS-1 was identified as a metastasis-suppressing gene in melanoma cells. The KiSS-1 gene product (metastin) was isolated from human placenta as the ligand of GPR54, a G-protein-coupled receptor. The role of metastin and GPR54 in tumor progression is not fully understood. METHODS: We inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Kazuyuki, Doi, Ryuichiro, Katagiri, Fumihiko, Ito, Tatsuo, Kida, Atsushi, Koizumi, Masayuki, Masui, Toshihiko, Kawaguchi, Yoshiya, Tomita, Kenji, Oishi, Shinya, Fujii, Nobutaka, Uemoto, Shinji
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639538/
https://www.ncbi.nlm.nih.gov/pubmed/19154616
http://dx.doi.org/10.1186/1756-9966-28-9
_version_ 1782164469578727424
author Nagai, Kazuyuki
Doi, Ryuichiro
Katagiri, Fumihiko
Ito, Tatsuo
Kida, Atsushi
Koizumi, Masayuki
Masui, Toshihiko
Kawaguchi, Yoshiya
Tomita, Kenji
Oishi, Shinya
Fujii, Nobutaka
Uemoto, Shinji
author_facet Nagai, Kazuyuki
Doi, Ryuichiro
Katagiri, Fumihiko
Ito, Tatsuo
Kida, Atsushi
Koizumi, Masayuki
Masui, Toshihiko
Kawaguchi, Yoshiya
Tomita, Kenji
Oishi, Shinya
Fujii, Nobutaka
Uemoto, Shinji
author_sort Nagai, Kazuyuki
collection PubMed
description BACKGROUND: KiSS-1 was identified as a metastasis-suppressing gene in melanoma cells. The KiSS-1 gene product (metastin) was isolated from human placenta as the ligand of GPR54, a G-protein-coupled receptor. The role of metastin and GPR54 in tumor progression is not fully understood. METHODS: We investigated the clinical significance of metastin and GPR54 expression in pancreatic cancer. We evaluated immunohistochemical expression of metastin and GPR54 in pancreatic ductal adenocarcinoma tissues obtained from 53 consecutive patients who underwent resection between July 2003 and May 2007 at Kyoto University Hospital. In 23 consecutive patients, the plasma metastin level was measured before surgery by enzyme immunoassay. RESULTS: Strong immunohistochemical expression of metastin was detected in 13 tumors (24.5%), while strong expression of GPR54 was detected in 30 tumors (56.6%). Tumors that were negative for both metastin and GPR54 expression were significantly larger than tumors that were positive for either metastin or GPR54 (p = 0.047). Recurrence was less frequent in patients who had metastin-positive tumors compared with those who had metastin-negative tumors (38.5% versus 70.0%, p = 0.04). Strong expression of metastin and GPR54 was significantly correlated with longer survival (p = 0.02). Metastin expression by pancreatic cancer was an independent prognostic factor for longer survival (hazard ratio, 2.1; 95% confidence interval, 1.1–4.7; p = 0.03), and the patients with a high plasma metastin level (n = 6) did not die after surgical resection. CONCLUSION: Strong expression of metastin and GPR54 by pancreatic cancer is associated with longer survival. Metastin expression is an independent prognostic factor for the survival of pancreatic cancer patients. The plasma metastin level could become a noninvasive prognostic factor for the assessment of pancreatic cancer.
format Text
id pubmed-2639538
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26395382009-02-11 Prognostic value of metastin expression in human pancreatic cancer Nagai, Kazuyuki Doi, Ryuichiro Katagiri, Fumihiko Ito, Tatsuo Kida, Atsushi Koizumi, Masayuki Masui, Toshihiko Kawaguchi, Yoshiya Tomita, Kenji Oishi, Shinya Fujii, Nobutaka Uemoto, Shinji J Exp Clin Cancer Res Research BACKGROUND: KiSS-1 was identified as a metastasis-suppressing gene in melanoma cells. The KiSS-1 gene product (metastin) was isolated from human placenta as the ligand of GPR54, a G-protein-coupled receptor. The role of metastin and GPR54 in tumor progression is not fully understood. METHODS: We investigated the clinical significance of metastin and GPR54 expression in pancreatic cancer. We evaluated immunohistochemical expression of metastin and GPR54 in pancreatic ductal adenocarcinoma tissues obtained from 53 consecutive patients who underwent resection between July 2003 and May 2007 at Kyoto University Hospital. In 23 consecutive patients, the plasma metastin level was measured before surgery by enzyme immunoassay. RESULTS: Strong immunohistochemical expression of metastin was detected in 13 tumors (24.5%), while strong expression of GPR54 was detected in 30 tumors (56.6%). Tumors that were negative for both metastin and GPR54 expression were significantly larger than tumors that were positive for either metastin or GPR54 (p = 0.047). Recurrence was less frequent in patients who had metastin-positive tumors compared with those who had metastin-negative tumors (38.5% versus 70.0%, p = 0.04). Strong expression of metastin and GPR54 was significantly correlated with longer survival (p = 0.02). Metastin expression by pancreatic cancer was an independent prognostic factor for longer survival (hazard ratio, 2.1; 95% confidence interval, 1.1–4.7; p = 0.03), and the patients with a high plasma metastin level (n = 6) did not die after surgical resection. CONCLUSION: Strong expression of metastin and GPR54 by pancreatic cancer is associated with longer survival. Metastin expression is an independent prognostic factor for the survival of pancreatic cancer patients. The plasma metastin level could become a noninvasive prognostic factor for the assessment of pancreatic cancer. BioMed Central 2009-01-21 /pmc/articles/PMC2639538/ /pubmed/19154616 http://dx.doi.org/10.1186/1756-9966-28-9 Text en Copyright © 2009 Nagai et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Nagai, Kazuyuki
Doi, Ryuichiro
Katagiri, Fumihiko
Ito, Tatsuo
Kida, Atsushi
Koizumi, Masayuki
Masui, Toshihiko
Kawaguchi, Yoshiya
Tomita, Kenji
Oishi, Shinya
Fujii, Nobutaka
Uemoto, Shinji
Prognostic value of metastin expression in human pancreatic cancer
title Prognostic value of metastin expression in human pancreatic cancer
title_full Prognostic value of metastin expression in human pancreatic cancer
title_fullStr Prognostic value of metastin expression in human pancreatic cancer
title_full_unstemmed Prognostic value of metastin expression in human pancreatic cancer
title_short Prognostic value of metastin expression in human pancreatic cancer
title_sort prognostic value of metastin expression in human pancreatic cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639538/
https://www.ncbi.nlm.nih.gov/pubmed/19154616
http://dx.doi.org/10.1186/1756-9966-28-9
work_keys_str_mv AT nagaikazuyuki prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT doiryuichiro prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT katagirifumihiko prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT itotatsuo prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT kidaatsushi prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT koizumimasayuki prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT masuitoshihiko prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT kawaguchiyoshiya prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT tomitakenji prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT oishishinya prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT fujiinobutaka prognosticvalueofmetastinexpressioninhumanpancreaticcancer
AT uemotoshinji prognosticvalueofmetastinexpressioninhumanpancreaticcancer